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ABSTRACT 
Tuberculosis (TB) is a bacterial disease responsible for millions of infections and preventable 
deaths each year. Its treatment is complicated by patients’ noncompliance due to dosing 
frequency, lengthy treatment, and adverse side effects associated with current chemotherapy. 
However, no modifications to the half-a-century old standard chemotherapy have been made 
based on a nanoformulation strategy to improve pharmacokinetic efficacy. In this study, we 
have designed a new nanodelivery formulation, using graphene oxide as the nanocarrier, loaded 
with the anti-TB antibiotic, ethambutol. The designed formulation was characterized using a 
number of molecular analytical techniques. It was found that sustained release of the drug 
resulted in better bioavailability. In addition, the designed formulation demonstrated high 
biocompatibility with mouse fibroblast cells. The anti-TB activity of the nanodelivery 
formulation was determined using whole-cell resazurin microtiter plate assay, modified-spot 
culture growth inhibition assay, and biofilm inhibition assay. The nanodelivery formulation 
showed good anti-mycobacterial activity. The anti-mycobacterial activity of Ethambutol was 
unaffected by the drug loading and release process. The results of this study demonstrated the 
potential of this new nanodelivery formulation strategy to be considered for modifying existing 
chemotherapy to yield more efficacious antibiotic treatment against TB. 
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